{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:51:14Z","timestamp":1787064674150,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To study the safety and efficacy of a personalised indocyanine\u2010guided pelvic lymph node dissection (PLND) against extended PLND (ePLND) during radical prostatectomy (RP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients who were candidates for RP and lymphadenectomy, with intermediate\u2010 or high\u2010risk prostate cancer (PCa) according to the National Comprehensive Cancer Network guidelines, were enrolled in this randomised clinical trial. Randomisation was made 1:1 to indocyanine green (ICG)\u2010PLND (only ICG\u2010stained LNs) or ePLND (obturator fossa, external, internal, and common iliac and presacral LNs). The primary endpoint was the complication rate within 3\u2009months after RP. Secondary endpoints included: rate of major complications (Clavien\u2013Dindo Grade III\u2010IV), time to drainage removal, length of stay, percentage of patients classified as pN1, number of LNs removed, number of metastatic LNs, rate of patients with undetectable prostate\u2010specific antigen (PSA), biochemical recurrence (BCR)\u2010free survival, and rate of patients with androgen\u2010deprivation therapy at 24\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 108 patients were included with a median follow\u2010up of 16\u2009months. In all, 54 were randomised to ICG\u2010PLND and 54 to ePLND. The postoperative complication rate was higher in the ePLND (70%) vs the ICG\u2010PLND group (32%) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Differences between major complications in both groups were not statically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.7). The pN1 detection rate was higher in the ICG\u2010PLND group (28%) vs the ePLND group (22%); however, this difference was not statistically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.7). The rate of undetectable PSA at 12\u2009months was 83% in the ICG\u2010PLND vs 76% in the ePLND group, which was not statistically significant. Additionally, there were no statistically significant differences in BCR\u2010free survival between groups at the end of the analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Personalised ICG\u2010guided PLND is a promising technique to stage patients with intermediate\u2010 and high\u2010risk PCa properly. It has shown a lower complication rate than ePLND with similar oncological outcomes at short\u2010term follow\u2010up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16117","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T12:49:50Z","timestamp":1688647790000},"page":"591-599","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Personalised indocyanine\u2010guided lymphadenectomy for prostate cancer: a randomised clinical trial"],"prefix":"10.1111","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-9893","authenticated-orcid":false,"given":"Pedro","family":"de Pablos\u2010Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Department of Urology, Research Institute of Biomedical and Health Sciences, Doctoral School of University of Las Palmas de Gran Canaria Instituto Valenciano de Oncolog\u00eda (IVO)  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-5553","authenticated-orcid":false,"given":"Francesco","family":"Claps","sequence":"additional","affiliation":[{"name":"Department of Urology Instituto Valenciano de Oncolog\u00eda (IVO)  Valencia Spain"},{"name":"Urology Clinic Department of Medicine, Surgery and Health Sciences University of Trieste  Trieste Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Rebez","sequence":"additional","affiliation":[{"name":"Urology Clinic Department of Medicine, Surgery and Health Sciences University of Trieste  Trieste Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Vidal Crespo","sequence":"additional","affiliation":[{"name":"Department of Urology Hospital General Universitario Santa Luc\u00eda  Murcia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"G\u00f3mez\u2010Ferrer","sequence":"additional","affiliation":[{"name":"Department of Urology Instituto Valenciano de Oncolog\u00eda (IVO)  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Mascar\u00f3s","sequence":"additional","affiliation":[{"name":"Department of Urology Instituto Valenciano de Oncolog\u00eda (IVO)  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argimiro","family":"Collado Serra","sequence":"additional","affiliation":[{"name":"Department of Urology Instituto Valenciano de Oncolog\u00eda (IVO)  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Caltrava Fons","sequence":"additional","affiliation":[{"name":"Department of Pathology Instituto Valenciano de Oncolog\u00eda (IVO)  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Rubio\u2010Briones","sequence":"additional","affiliation":[{"name":"Department of Urology Instituto Valenciano de Oncolog\u00eda (IVO)  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Casanova Ramon Borja","sequence":"additional","affiliation":[{"name":"Department of Urology Instituto Valenciano de Oncolog\u00eda (IVO)  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Ram\u00edrez Backhaus","sequence":"additional","affiliation":[{"name":"Department of Urology Instituto Valenciano de Oncolog\u00eda (IVO)  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.10.057"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.044"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.10.012"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.025"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.003"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.03.012"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000049032.38743.c7"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.03.006"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.040"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.02.001"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"e983","DOI":"10.1016\/j.juro.2015.02.2565","article-title":"Extended vs limited pelvic lymphadenectomy during radical prostatectomy for intermediate\u2010 and high\u2010risk prostate cancer: a prospective randomized trial","volume":"193","author":"Lestingi J","year":"2015","journal-title":"J Urol"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(14)60266-9"},{"key":"e_1_2_11_14_1","volume-title":"Molecular Imaging and Contrast Agent Database (MICAD)","author":"Leung K","year":"2011"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.05.087"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.08.005"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.11.015"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.033"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.011"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14906"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.10.072"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64055-4"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.08.015"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.017"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.03.127"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.014"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.01.034"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05580-0"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.06.002"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:30:38Z","timestamp":1761741038000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/bju.16117"],"URL":"https:\/\/doi.org\/10.1111\/bju.16117","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"2023-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}